$12.30
9.33% yesterday
Nasdaq, Oct 15, 10:02 pm CET
ISIN
US75901B1070
Symbol
RGNX

REGENXBIO, Inc. Target price 2025 - Analyst rating & recommendation

REGENXBIO, Inc. Classifications & Recommendation:

Buy
89%
Hold
11%

REGENXBIO, Inc. Price Target

Target Price $34.68
Price $12.30
Potential
Number of Estimates 15
15 Analysts have issued a price target REGENXBIO, Inc. 2026 . The average REGENXBIO, Inc. target price is $34.68. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 19 analysts: 17 Analysts recommend REGENXBIO, Inc. to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the REGENXBIO, Inc. stock has an average upside potential 2026 of . Most analysts recommend the REGENXBIO, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 83.33 253.14
7.66% 203.78%
EBITDA Margin -256.97% -12.03%
7.55% 95.32%
Net Margin -272.53% -49.15%
6.66% 81.97%

15 Analysts have issued a sales forecast REGENXBIO, Inc. 2025 . The average REGENXBIO, Inc. sales estimate is

$253m
Unlock
. This is
62.50% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$438m 181.07%
Unlock
, the lowest is
$148m 4.76%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $83.3m 7.66%
2025
$253m 203.78%
Unlock
2026
$255m 0.72%
Unlock
2027
$383m 50.12%
Unlock
2028
$481m 25.58%
Unlock
2029
$645m 34.20%
Unlock
2030
$830m 28.72%
Unlock
2031
$1.0b 21.41%
Unlock
2032
$1.0b 3.37%
Unlock

9 Analysts have issued an REGENXBIO, Inc. EBITDA forecast 2025. The average REGENXBIO, Inc. EBITDA estimate is

$-30.5m
Unlock
. This is
79.52% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$132m 188.94%
Unlock
, the lowest is
$-188m 26.07%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-214m 14.62%
2025
$-30.5m 85.78%
Unlock
2026
$-135m 344.15%
Unlock
2027
$-60.7m 55.16%
Unlock
2028
$-62.1m 2.30%
Unlock
2029
$75.7m 222.03%
Unlock
2030
$178m 135.61%
Unlock
2031
$189m 5.89%
Unlock
2032
$217m 14.98%
Unlock

EBITDA Margin

2024 -256.97% 7.55%
2025
-12.03% 95.32%
Unlock
2026
-53.06% 341.06%
Unlock
2027
-15.85% 70.13%
Unlock
2028
-12.91% 18.55%
Unlock
2029
11.74% 190.94%
Unlock
2030
21.49% 83.05%
Unlock
2031
18.74% 12.80%
Unlock
2032
20.85% 11.26%
Unlock

15 REGENXBIO, Inc. Analysts have issued a net profit forecast 2025. The average REGENXBIO, Inc. net profit estimate is

$-124m
Unlock
. This is
29.14% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$48.8m 127.82%
Unlock
, the lowest is
$-211m 20.10%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-227m 13.81%
2025
$-124m 45.22%
Unlock
2026
$-124m 0.61%
Unlock
2027
$-79.2m 35.94%
Unlock
2028
$-82.5m 4.14%
Unlock
2029
$-7.7m 90.65%
Unlock
2030
$123m 1,689.88%
Unlock
2031
$420m 242.98%
Unlock
2032
$420m 0.00%
Unlock

Net Margin

2024 -272.53% 6.66%
2025
-49.15% 81.97%
Unlock
2026
-48.50% 1.32%
Unlock
2027
-20.70% 57.32%
Unlock
2028
-17.16% 17.10%
Unlock
2029
-1.20% 93.01%
Unlock
2030
14.76% 1,330.00%
Unlock
2031
41.71% 182.59%
Unlock
2032
40.35% 3.26%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -4.59 -2.47
23.75% 46.19%
P/E negative
EV/Sales 1.18

15 Analysts have issued a REGENXBIO, Inc. forecast for earnings per share. The average REGENXBIO, Inc. EPS is

$-2.47
Unlock
. This is
27.57% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$0.97 128.45%
Unlock
, the lowest is
$-4.18 22.58%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-4.59 23.75%
2025
$-2.47 46.19%
Unlock
2026
$-2.45 0.81%
Unlock
2027
$-1.57 35.92%
Unlock
2028
$-1.64 4.46%
Unlock
2029
$-0.15 90.85%
Unlock
2030
$2.43 1,720.00%
Unlock
2031
$8.34 243.21%
Unlock
2032
$8.34 0.00%
Unlock

P/E ratio

Current -3.61 71.41%
2025
-4.98 38.06%
Unlock
2026
-5.01 0.60%
Unlock
2027
-7.82 56.09%
Unlock
2028
-7.51 3.96%
Unlock
2029
-80.39 970.44%
Unlock
2030
5.06 106.29%
Unlock
2031
1.47 70.95%
Unlock
2032
1.47 0.00%
Unlock

Based on analysts' sales estimates for 2025, the REGENXBIO, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.91 31.05%
2025
1.18 38.36%
Unlock
2026
1.17 0.71%
Unlock
2027
0.78 33.39%
Unlock
2028
0.62 20.36%
Unlock
2029
0.46 25.50%
Unlock
2030
0.36 22.29%
Unlock
2031
0.30 17.63%
Unlock
2032
0.29 3.28%
Unlock

P/S ratio

Current 3.99 31.19%
2025
2.45 38.46%
Unlock
2026
2.44 0.71%
Unlock
2027
1.62 33.39%
Unlock
2028
1.29 20.37%
Unlock
2029
0.96 25.48%
Unlock
2030
0.75 22.31%
Unlock
2031
0.62 17.64%
Unlock
2032
0.60 3.26%
Unlock

Current REGENXBIO, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Oct 07 2025
HC Wainwright & Co.
Locked
Locked
Locked Sep 08 2025
Chardan Capital
Locked
Locked
Locked Sep 08 2025
HC Wainwright & Co.
Locked
Locked
Locked Aug 19 2025
Barclays
Locked
Locked
Locked Aug 08 2025
RBC Capital
Locked
Locked
Locked Aug 08 2025
Chardan Capital
Locked
Locked
Locked Aug 08 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Oct 07 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Sep 08 2025
Locked
Chardan Capital:
Locked
Locked
Sep 08 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 19 2025
Locked
Barclays:
Locked
Locked
Aug 08 2025
Locked
RBC Capital:
Locked
Locked
Aug 08 2025
Locked
Chardan Capital:
Locked
Locked
Aug 08 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today